Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

In silico Modeling of the Impact of Antithrombin Lowering on Thrombin Generation in Rare Bleeding Disorders

Gautham Sridharan, PhD, Jingxuan Liu, PhD, Kun Qian, M.S., Varun Goel, PhD, Stephen Huang, MD, Akin Akinc, PhD

Blood (2017) 130 (Supplement 1): 3659.

https://doi.org/10.1182/blood.V130.Suppl_1.3659.3659

Published: 2017

Journal Articles

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors

K John Pasi, Pencho Georgiev, Tim Mant, Toshko Lissitchkov, Michael Desmond Creagh, David Bevan, Steve Austin, Charles R Hay, Inga Hegemann, Rashid Kazmi, Pratima Chowdary, Margaret V. Ragni, MD, Chang-Heok Soh, Akin Akinc, Angela M. Partisano, Benny Sorenson, Savita Rangarajan

Blood (2016) 128 (22): 1397.

https://doi.org/10.1182/blood.V128.22.1397.1397

Published: 2016

Journal Articles

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

Margaret V. Ragni, MD, Pencho Georgiev, Tim Mant, Michael Desmond Creagh, Toshko Lissitchkov, David Bevan, Steve Austin, Charles R Hay, Inga Hegemann, Rashid Kazmi, Pratima Chowdary, Savita Rangarajan, Chang-Heok Soh, Akin Akinc, Angela M. Partisano, Benny Sorenson, K John Pasi

Blood (2016) 128 (22): 2572.

https://doi.org/10.1182/blood.V128.22.2572.2572

Published: 2016

Journal Articles

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

K John Pasi, Pencho Georgiev, Tim Mant, Michael Desmond Creagh, Toshko Lissitchkov, MD, David Bevan, Steve Austin, Charles R Hay, Brigit Brand, Rashid Kazmi, Pratima Chowdary, Margaret V Ragni, Jihong Chen, Akin Akinc, Benny Sorensen, Savita Rangarajan

Blood (2015) 126 (23): 551.

https://doi.org/10.1182/blood.V126.23.551.551

Published: 2015

Journal Articles

Antithrombin Reduction Corrected Thrombin Generation in Samples from Hemophilia A and B Patients with Inhibitors

Gili Kenet, Tami Livnat, Emma Fosbury, Pratima Chowdary, Alfica Sehgal, Akin Akinc, Benny Sorensen

Blood (2015) 126 (23): 552.

https://doi.org/10.1182/blood.V126.23.552.552

Published: 2015

Journal Articles

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Benny Sorensen, MD PhD, Tim Mant, MD, Akin Akinc, PhD, Amy Simon, MD, Lauren Melton, Christian Lynam, Andrew Strahs, PhD, Alfica Sehgal, PhD, Renta Hutabarat, PhD, Prasoon Chaturvedi, PhD, Scott Barros, PhD, Akshay Vaishnaw, MD PhD, Aln-AT Investigators

Blood (2014) 124 (21): 693.

https://doi.org/10.1182/blood.V124.21.693.693

Published: 2014

Journal Articles

Expanded Therapeutic Index Of Antithrombin Silencing and Correction Of Aptt In a Hemophilia A Mouse Model

Scott A Barros, PhD, DABT, Mary Carioto, Julia Hettinger, Yongfeng Jiang, June Qin, Harsha Prabhala, Alfica Sehgal, PhD, Akin Akinc, PhD

Blood (2013) 122 (21): 3585.

https://doi.org/10.1182/blood.V122.21.3585.3585

Published: 2013

Journal Articles

An RNAi Therapeutic Targeting Antithrombin Increases Thrombin Generation in Nonhuman Primates

Akin Akinc, PhD, Alfica Sehgal, PhD, Scott Barros, PhD, Julia Hettinger, Klaus Charisse, PhD, Josh Brodsky, June Qin, Tim Racie

Blood (2012) 120 (21): 3370.

https://doi.org/10.1182/blood.V120.21.3370.3370

Published: 2012

Journal Articles

Treatment of erythropoietin deficiency in mice with systemically administered siRNA

William Querbes, Roman L. Bogorad, Javid Moslehi, Jamie Wong, Amy Y. Chan, Elena Bulgakova, Satya Kuchimanchi, Akin Akinc, Kevin Fitzgerald, Victor Koteliansky, William G. Kaelin, Jr

Blood (2012) 120 (9): 1916–1922.

https://doi.org/10.1182/blood-2012-04-423715

Published: 2012

Includes: Supplemental data

Journal Articles

Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia

Akin Akinc, PhD, Amy Chan-Daniels, PhD, Alfica Sehgal, PhD, Don Foster, Brian R Bettencourt, PhD, Julia Hettinger, Tim Racie, Justin Aubin, Satya Kuchimanchi, PhD, Hila Epstein-Barash, PhD, Tomoko Nakayama, PhD

Blood (2011) 118 (21): 688.

https://doi.org/10.1182/blood.V118.21.688.688

Published: 2011

Journal Articles

Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis,

William Querbes, PhD, Roman Bogorad, PhD, Javid Moslehi, MD, Akin Akinc, PhD, Jamie Wong, PhD, Chris Zurenko, June Qin, Julia Hettinger, Satya Kuchimanchi, PhD, Klaus Charisse, PhD, Dinah WY Sah, PhD, Kevin Fitzgerald, PhD, Victor Kotelianski, MD, PhD, William G. Kaelin, Jr., MD

Blood (2011) 118 (21): 3161.

https://doi.org/10.1182/blood.V118.21.3161.3161

Published: 2011

NARROW

In silico Modeling of the Impact of Antithrombin Lowering on Thrombin Generation in Rare Bleeding Disorders

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients with Inhibitors

Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia: Updated Results from a Phase 1 and Phase 1/2 Extension Study in Patients without Inhibitors

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

Antithrombin Reduction Corrected Thrombin Generation in Samples from Hemophilia A and B Patients with Inhibitors

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Expanded Therapeutic Index Of Antithrombin Silencing and Correction Of Aptt In a Hemophilia A Mouse Model

An RNAi Therapeutic Targeting Antithrombin Increases Thrombin Generation in Nonhuman Primates

Treatment of erythropoietin deficiency in mice with systemically administered siRNA

Targeting the Hepcidin Pathway with RNAi Therapeutics for the Treatment of Anemia

Liver Specific Delivery of siRNA Targeting EGLN Prolyl Hydroxylases Activates Hepatic Erythropoietin Production and Stimulates Erythropoiesis,

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only